Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death

被引：1
|
作者：
Friedrich, Jan O.
Adhikari, Neill K. J.
Meade, Maureen O.
机构：
[1] Univ Toronto, St Michaels Hosp, Crit Care Dept, Interdept Div Crit Care, Toronto, ON M5B 1W8, Canada
[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Interdept Div Crit Care, Toronto, ON M4N 3M5, Canada
[3] McMaster Univ, Dept Med, Dept Crit Care, Hamilton, ON L8N 3Z5, Canada
[4] McMaster Univ, Dept Clin Epidemiol & Biostat, Dept Crit Care, Hamilton, ON L8N 3Z5, Canada
来源：
CRITICAL CARE | 2006年 / 10卷 / 06期
关键词：
Random Effect; Severe Sepsis; Health Evaluation; Fixed Effect Model; Methodologic Difference;
D O I：
10.1186/cc5117
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
    Jan O Friedrich
    Neill KJ Adhikari
    Maureen O Meade
    [J]. Critical Care, 10
  • [2] Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    Abraham, E
    Laterre, P
    Garg, R
    Levy, H
    Talwar, D
    Trzaskoma, BL
    Francois, B
    Guy, JS
    Bruckmann, M
    Rea-Neto, A
    Rossaint, R
    Perrotin, D
    Sablotzki, A
    Arkins, N
    Utterback, BG
    Macias, WL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13): : 1332 - 1341
  • [3] Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death
    Sanjay Gupta
    Eric B Milbrandt
    Lakshmipathi Chelluri
    [J]. Critical Care, 10
  • [4] Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
    Williams, Mark D.
    Janes, Jonathan M.
    Nelson, David R.
    [J]. CRITICAL CARE, 2006, 10 (05):
  • [5] Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death
    Gupta, Sanjay
    Milbrandt, Eric B.
    Chelluri, Lakshmipathi
    [J]. CRITICAL CARE, 2006, 10 (06):
  • [6] Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
    Mark D Williams
    Jonathan M Janes
    David R Nelson
    [J]. Critical Care, 10
  • [7] Hemorrhagic risk of (activated) drotrecogin alfa in severe sepsis
    Perrotin, D
    [J]. ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2003, 22 : 16 - 19
  • [8] Drotrecogin alfa (activated) in severe sepsis
    Baillie, JK
    Murray, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01): : 95 - 95
  • [9] Drotrecogin alfa (activated) in severe sepsis
    Janes, Jonathan M.
    Vangerow, Burkhard
    Costigan, Timothy M.
    Macias, William L.
    [J]. LANCET INFECTIOUS DISEASES, 2013, 13 (02): : 108 - 109
  • [10] Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis
    Barie, PS
    Williams, MD
    McCollam, JS
    Bates, BM
    Qualy, RL
    Lowry, SF
    Fry, DE
    [J]. AMERICAN JOURNAL OF SURGERY, 2004, 188 (03): : 212 - 220
12345